Marketed products, 21 CFR 314.80. The applicant reviews adverse drug experience information from any source, foreign or domestic, and:
- sends a 15-day Alert report for each experience that is serious and unexpected, foreign or domestic, within 15 calendar days of first receipt, with follow-ups within 15 days of new information;
- for a case from a postmarketing study, sends one only if it concludes there is a reasonable possibility the drug caused it;
- may receive serious reports from a nonapplicant named on the label (a manufacturer, packer or distributor), which then has 5 calendar days to send them;
- submits electronically, codes patients rather than naming them, and keeps adverse drug experience records for 10 years.
IND trials, 21 CFR 312.32. The sponsor notifies FDA and all participating investigators in an IND safety report within 15 calendar days of deciding a case qualifies, or within 7 calendar days of first receipt for an unexpected fatal or life-threatening suspected adverse reaction. Each report names earlier similar reports and analyses the significance. Since 1 April 2026, FDA receives these reports electronically, in E2B(R3) format, in its Adverse Event Monitoring System (AEMS, formerly FAERS).